Keyword: OncoMed Pharmaceuticals
The announcement comes nearly three months after Mereo and OncoMed unveiled their reverse merger.
SITC kicked off with a stack of new data on immuno-oncology drugs, including a first look at Merck’s early-stage drugs targeting LAG-3 and TIGIT.
It doesn’t rain, but it pours in April for OncoMed: Last week, it had a double dose of bad news when it revealed that its Celgene-partnered lead asset demcizumab had flunked a phase 2 pancreatic cancer trial and Bayer had walked away from two drugs, triggering a 40% drop in its stock price.
OncoMed shares tanked after its Celgene-partnered lead asset flunked a phase 2 pancreatic cancer trial and Bayer walked away from two drugs.